Cabaletta Bio (CABA) Stock Forecast & Price Target

Compare

1,393 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CABA Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Cabaletta

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CABA Stock 12 Month Forecast

Average Price Target

$17.83

▲(613.20% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $17.83 with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 613.20% change from the last price of $2.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","31":"$31","7.75":"$7.75","15.5":"$15.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7.75,15.5,23.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,5.640000000000001,7.67,9.700000000000001,11.73,13.760000000000002,15.790000000000001,17.82,19.85,21.880000000000003,23.910000000000004,25.94,27.970000000000002,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.703846153846154,5.797692307692307,6.891538461538461,7.985384615384614,9.079230769230769,10.173076923076922,11.266923076923076,12.360769230769229,13.454615384615384,14.548461538461536,15.64230769230769,16.736153846153844,{"y":17.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.101538461538461,4.593076923076923,5.084615384615384,5.576153846153846,6.067692307692308,6.559230769230769,7.050769230769231,7.542307692307693,8.033846153846154,8.525384615384615,9.016923076923078,9.508461538461539,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$17.83

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Roger Song

Jefferies

$14

Buy

460.00%

Upside

Reiterated

11/18/25

Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)

Douglas Tsao

H.C. Wainwright

$2.34→$16

Buy

540.00%

Upside

Reiterated

11/14/25

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

Yatin Suneja

Guggenheim

$15

Buy

500.00%

Upside

Reiterated

11/12/25

Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/10/25

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating

Michael Ulz

Morgan Stanley

$22

Buy

780.00%

Upside

Reiterated

11/10/25

Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating

Joshua Schimmer

Cantor Fitzgerald

$15→$30

Buy

1100.00%

Upside

Reiterated

10/30/25

Analysts Are Bullish on Top Healthcare Stocks: Cabaletta Bio (CABA), Gilead Sciences (GILD)We're increasing our CABA PT from $15 to $30.

Samantha Semenkow

Citi

$10

Buy

300.00%

Upside

Reiterated

10/10/25

Promising Early Data from Cabaletta Bio's Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment

Gavin Clark-Gartner

Evercore ISI

Hold

60.00%

Upside

Reiterated

08/11/25

Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA)Earnings Overload SMID Biotech Week in Review

Derek Archila

Wells Fargo

$3→$2

Hold

-20.00%

Downside

Reiterated

08/08/25

Wells Fargo Sticks to Its Hold Rating for Cabaletta Bio (CABA)

Trung Huynh

UBS

$10→$7

Buy

180.00%

Upside

Reiterated

04/01/25

Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Roger Song

Jefferies

$14

Buy

460.00%

Upside

Reiterated

11/18/25

Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)

Douglas Tsao

H.C. Wainwright

$2.34→$16

Buy

540.00%

Upside

Reiterated

11/14/25

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

Yatin Suneja

Guggenheim

$15

Buy

500.00%

Upside

Reiterated

11/12/25

Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/10/25

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating

Michael Ulz

Morgan Stanley

$22

Buy

780.00%

Upside

Reiterated

11/10/25

Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating

Joshua Schimmer

Cantor Fitzgerald

$15→$30

Buy

1100.00%

Upside

Reiterated

10/30/25

Analysts Are Bullish on Top Healthcare Stocks: Cabaletta Bio (CABA), Gilead Sciences (GILD)We're increasing our CABA PT from $15 to $30.

Samantha Semenkow

Citi

$10

Buy

300.00%

Upside

Reiterated

10/10/25

Promising Early Data from Cabaletta Bio's Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment

Gavin Clark-Gartner

Evercore ISI

Hold

60.00%

Upside

Reiterated

08/11/25

Evercore ISI Reaffirms Their Hold Rating on Cabaletta Bio (CABA)Earnings Overload SMID Biotech Week in Review

Derek Archila

Wells Fargo

$3→$2

Hold

-20.00%

Downside

Reiterated

08/08/25

Wells Fargo Sticks to Its Hold Rating for Cabaletta Bio (CABA)

Trung Huynh

UBS

$10→$7

Buy

180.00%

Upside

Reiterated

04/01/25

Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cabaletta Bio

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+3.47%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.47% per trade.

3 Months

xxx

Success Rate

15/23 ratings generated profit

Average Return

+21.40%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +21.40% per trade.

1 Year

Sami CorwinWilliam Blair

Success Rate

9/15 ratings generated profit

Average Return

-8.91%

reiterated a buy rating last month

Copying Sami Corwin's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -8.91% per trade.

2 Years

xxx

Success Rate

9/15 ratings generated profit

Average Return

-6.06%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of -6.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CABA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CABA has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CABA average Analyst price target in the past 3 months is 17.83.

Each month's total comprises the sum of three months' worth of ratings.

CABA Financial Forecast

CABA Earnings Forecast

Next quarter’s earnings estimate for CABA is -$0.46 with a range of -$0.47 to -$0.44. The previous quarter’s EPS was -$0.44. CABA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CABA has Performed in-line its overall industry.

No data currently available

CABA Sales Forecast

Next quarter’s sales forecast for CABA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CABA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CABA has Performed in-line its overall industry.

CABA Stock Forecast FAQ

What is CABA’s average 12-month price target, according to analysts?

Based on analyst ratings, Cabaletta Bio’s 12-month average price target is 17.83.

What is CABA’s upside potential, based on the analysts’ average price target?

Cabaletta Bio has 613.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CABA a Buy, Sell or Hold?

Cabaletta Bio has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cabaletta Bio’s price target?

The average price target for Cabaletta Bio is 17.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $10.00. The average price target represents 613.20% Increase from the current price of $2.5.

What do analysts say about Cabaletta Bio?

Cabaletta Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CABA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cabaletta Bio (CABA) Stock Forecast & Price Target

CABA Analyst Ratings

CABA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cabaletta Bio

CABA Analyst Recommendation Trends

CABA Financial Forecast

CABA Earnings Forecast

CABA Sales Forecast

CABA Stock Forecast FAQ

Detailed List of Analyst Forecasts